

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: CIGNA CORP - Form 8-K/A

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 2, 2018, Cigna Corporation (the “Company”) filed a Current Report on Form 8-K announcing the appointment of Dr. Mark McClellan to the Company’s Board of Directors (the “Board”) effective December 1, 2018. At that time, the Board had not determined on which committees Dr. McClellan would serve. This Form 8-K/A is being filed for the purpose of providing this information.

Effective December 6, 2018, Dr. McClellan was appointed to the Audit Committee and the Corporate Governance Committee of the Board.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cigna Corporation

Date: December 10, 2018 By: /s/ Nicole S. Jones
Nicole S. Jones
Executive Vice President and
General Counsel